HCW Biologics Inc. (HCWB): Nasdaq/NYSE listing notice — HCW Biologics receives Nasdaq delisting notice for failure to meet MVLS minimum of $50M

HCW Biologics Inc.

Nasdaq notified HCW Biologics on Dec 17, 2024 that its securities are subject to delisting due to MVLS below $50M threshold for 30 consecutive business days.
Company failed to regain compliance by the Dec 16, 2024 deadline after a 180-day compliance period that began June 20, 2024.
HCW Biologics plans to timely request a hearing before Nasdaq Hearing Panel, which will stay delisting pending hearing and possible extension.
Panel may grant up to 180-day extension; no assurance of continued listing.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

HCW Biologics Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(3)(A)

Exact text from the filing

December 17, 2024, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the hearing and the expiration of any extension that may be granted to the Company following the hearing. At the hearing, the Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time

View on SEC.gov

Browse all listing & compliance notices →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-139288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.